An open-label, dose escalation phase 1 study of MLN8054 [MLN-8054], a novel aurora a kinase inhibitor, in patients with advanced solid tumors

Trial Profile

An open-label, dose escalation phase 1 study of MLN8054 [MLN-8054], a novel aurora a kinase inhibitor, in patients with advanced solid tumors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2008

At a glance

  • Drugs MLN 8054 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Feb 2008 Status changed from rercruiting to terminated, according to clinicaltrials.gov
    • 27 Jul 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top